Sensoril® is a superior, next-generation Ashwagandha extract that represents a major advancement over root-only extracts because both roots and leaves are used in Sensoril.
Brattleboro, VT (PRWEB) June 30, 2014
In a recent study published in the peer reviewed Journal of Clinical Psychiatry, the multi-patented, GRAS-affirmed, standardized Ashwagandha root and leaf extract, Sensoril®, was shown to improve several areas of cognitive effect in subjects with bipolar disorder. NutraGenesis is the exclusive North American sales and marketing representative for Sensoril® under license from Natreon, Inc. (New Brunswick, NJ).
The study was conducted at Western Psychiatric Institute and Clinic-University of Pittsburgh Medical Center. An investigational new drug application (IND) was submitted to the US Food and Drug Administration and approval was obtained to use Sensoril® in the study because it met FDA-approved safety guidelines. Sixty subjects with bipolar disorder were enrolled in a 8 week, double-blind, placebo-controlled study. Compared to placebo, Sensoril® showed significantly greater benefits for 3 cognitive tasks, digit span backward, Flanker neutral response time and the social cognition response rating of the Penn Emotional Acuity Test.
“Modern research and chemistry have identified several bioactive constituents in Ashwagandha that have significant cognitive enhancing benefits, namely the steroidal lactones which are known as glycowithanolides and sitoindosides,” states Dr. Sanni Raju CEO and Chairman of the Board of Natreon, Inc. “Glycowithanolides are brain antioxidants which can promote neuroprotective and memory enhancing activity”, he added.
“Multi-patented, clinically proven Sensoril® was the ideal test agent for this study. Sensoril® is a superior, next-generation Ashwagandha extract that represents a major advancement over root-only extracts because both roots and leaves are used in Sensoril’s proprietary, water-based extraction process”, said NutraGenesis, LLC President and Managing Director, Suzanne McNeary. “Ashwagandha leaves are naturally richer in glycowithanolide bioactive content. The unique use of leaves in addition to roots in Sensoril® (based on intellectual property surrounding the extract) results in Sensoril® having the highest levels if glycowithanolide bioactives (standardized to a minimum of 10%) of any commercial extract available on the market today. In addition, Sensoril® is the only Ashwagandha nutraceutical sold today for which an IND has been granted as a result of Sensoril’s comprehensive safety profile and its commercial use in North America for over 12 years,” she added.
Sensoril® root and leaf extract possesses multiple health benefits, superior efficacy demonstrated in 8 randomized, double-blind, placebo controlled human clinical trials, broad IP status including multiple patents, and a comprehensive safety record. That’s why Sensoril® is best selling, branded Ashwagandha extract of choice in the North American market. Sensoril® is now used in over 200 SKU’s to help support stress, mental cognition, fatigue-reduction, sleep, metabolic wellness, adrenal function, thyroid function, sports performance, and more.
About NutraGenesis: Located in the Connecticut River Valley area of Southern Vermont, NutraGenesis LLC is a diversified nutraceutical product marketing company dedicated to the development and commercialization of proprietary, scientifically researched, health-promoting ingredients. NutraGenesis is the exclusive North American sales and marketing agent for Sensoril®.
About Natreon: Natreon is a 15-year-old company with headquarters in New Jersey, with a diversified portfolio of scientifically researched and clinically studies Ayurvedic ingredients. Sensoril® is protected by U.S. Patents 6,153,198; 6,713,092 and 7,318,938; European Patent EP1569669 A2; and Canadian Patent 2,508,478. Sensoril® is a trademark of Natreon, Inc.